DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Azacitidine in lower-risk myelodysplastic syndromes.

Author(s): Santini V

Affiliation(s): UF Ematologia, Azienda Ospedaliero-Universitaria (AOU) Careggi, Universita degli Studi di Firenze, Florence, Italy. santini@unifi.it

Publication date & source: 2009-12, Leuk Res., 33 Suppl 2:S22-6.

Azacitidine is the first agent to significantly prolong overall survival (OS) compared with conventional care regimens in patients with higher-risk myelodysplastic syndromes (MDS). Here, we review currently available data on azacitidine treatment in lower-risk MDS. In a phase III study, a subset of patients with lower-risk MDS treated with azacitidine achieved an overall response rate (ORR) of 60% and a longer median OS compared with supportive care (44 vs 27 months). In a phase II study investigating various azacitidine dose schedules, the hematological improvement rate was approximately 50% in lower-risk patients; most patients who achieved transfusion independence were also lower-risk. A further retrospective study reported an ORR of 52% in MDS lower-risk patients who received > or = 4 cycles of therapy. Preliminary data for azacitidine combination therapy with erythropoietin, granulocyte colony-stimulating factor, and valproic acid are intriguing but should be treated with caution. These results suggest the feasibility and effectiveness of azacitidine in the treatment of patients with lower-risk MDS.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017